Search clinical trials for: Meningococcal serogroup X

Total 30441 results

Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Meningitis

Mali
Serum Institute of India Pvt. Ltd.
PATH

Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Meningitis, Meningococcal

Mali
Serum Institute of India Pvt. Ltd.
PATH

Completed

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Meningococcal Meningitis

Gambia, Mali
PATH

Completed

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

Meningococcal Vaccines

United States
GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
CanSino Biologics Inc.

Recruiting

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Epidemic Meningitis

China
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi Pasteur, a Sanofi Company

Recruiting

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam

Healthy Volunteers | Meningococcal Infection

Vietnam
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Meningococcal Infection (Healthy Volunteers)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
University of Oxford
Norwegian Institute of Public Health; Wellcome Trust

Completed

MenPF-1 - A New Vaccine Against Meningococcal Disease

Serogroup B Meningococcal Disease

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Butantan Institute

Completed

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza (Xo_Gripe)

Influenza | Acute Respiratory Infection

Brazil
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
University of Oxford

Active, not recruiting

Sero-epidemiological Survey of England in 2019/2020 - COVID-19 (STORY)

COVID-19 | Diphtheria | Serogroup C Meningococcal Meningitis

United Kingdom
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
UCSF Benioff Children's Hospital Oakland
University of Massachusetts, Worcester

Completed

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Meningococcal Infections

United States
London School of Hygiene and Tropical Medicine
Public Health England; Stanford University; World Health Organization; University... and other collaborators

Unknown

Maternal Immunization With MenAfriVac™

Meningitis | Meningococcal

Gambia
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
Walvax Biotechnology Co., Ltd.

Completed

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Meningococcal Infections

China
Pfizer

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Meningococcal Infection

Mexico, Lebanon
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
Public Health England
Institute of Child Health; National Institute of Biological Standards and Control

Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile
Canadian Immunization Research Network
University of British Columbia; University of Calgary; Dalhousie University; Université...

Completed

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Meningococcal Serogroup B

Canada
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States

3

Subscribe